US00182C1036
US00182C1036
ANI Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 883.366.000 | 614.376.000 | 43.8% |
| Cost of Revenue | 341.310.000 | 250.210.000 | 36.4% |
| Gross Profit | 542.056.000 | 364.166.000 | 48.8% |
| 460.826.000 | 361.948.000 | 27.3% | |
| Operating Income | 81.230.000 | 2.218.000 | 3562.3% |
| Pretax Income | 95.791.000 | -22.212.000 | 531.3% |
| Net Income Common Stockholders | 70.217.000 | -20.147.000 | 448.5% |
| -- | -- | -- | |
| -- | -- | -- |